 1. Subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in Study CC-4047-MM-003 and discontinued study therapy with dexamethasone alone Treatment Arm B after at least starting the second cycle of dexamethasone treatment and due to development of documented disease progression according to the International Myeloma Working Group IMWG criteria and as decided by an Independent Review Adjudication Committee IRAC. 